The first GLP-1/GIP/glucagon triple agonist. In Phase 2 (Jastreboff et al., NEJM 2023, n=338), adults at the 12 mg dose lost an average of 24.2% body weight at 48 weeks — the largest mean weight loss reported for any obesity medication in a Phase 2 trial.
$113.75 per weekly dose
Start Free AssessmentGet started in 3 simple steps. No office visits required.
Answer a few health questions. Our board-certified physicians review your medical history and determine if Retatrutide is right for you.
If approved, your prescription is sent to our partner pharmacy. Your medication is compounded fresh and shipped directly to your door.
Inject weekly at home. Track your progress with our app. Our care team is available 24/7 for support and dose adjustments.
Clinically proven weight management therapy prescribed by board-certified physicians.
Up to 24.2% body weight reduction in clinical trials
Targets GLP-1, GIP, and glucagon receptors simultaneously
Simple injection, no daily pills to remember
Improves A1c, blood pressure, and cholesterol
Phase 2 results demonstrating efficacy and safety.
Phase 2 data — Jastreboff et al., NEJM 2023. Retatrutide demonstrates significant clinical efficacy.
Mechanism of Action
Reduces appetite, slows gastric emptying, and increases insulin secretion
Enhances insulin sensitivity and amplifies the metabolic effects of GLP-1
Increases energy expenditure and promotes fat burning while preserving muscle
Important information about Retatrutide safety and side effects.
Everything you need to know about Retatrutide.
Retatrutide is a triple hormone receptor agonist — glp-1, gip, and glucagon receptors. Our physicians prescribe it based on your individual health profile to achieve optimal therapeutic outcomes.
Based on clinical evidence, 24.2% weight loss at 48 weeks. Individual results vary based on adherence, health status, and other factors. Our care team monitors your progress throughout treatment.
Retatrutide is administered via subcutaneous injection weekly. Your shipment includes pre-filled syringes, alcohol swabs, and a sharps container. Our care team provides injection training.
The most common side effects include Nausea, Diarrhea, Constipation. These are typically mild and may improve over time. Our physicians monitor your response and can adjust dosing to minimize side effects. Contact our care team if you experience any concerning symptoms.
Individual results vary, but clinical trials showed significant weight reduction. Most patients begin noticing changes within 4-8 weeks, with maximum results typically seen at 6-12 months of consistent use. Your physician will monitor your progress and adjust dosing as needed.
Real reviews from verified ArgoMD patients.
Down 47 lbs in 5 months on Retatrutide. The process was so easy — filled out the form online, doctor approved me same day, and my medication arrived 2 days later. The weekly injection is way easier than I expected.
After trying every diet imaginable, Retatrutide finally gave me the tool I needed. I've lost 32 lbs and my energy is through the roof. The care team checks in regularly which keeps me accountable.
The onboarding was seamless. I was nervous about the injection but it's so easy. I've lost 38 lbs in 4 months and my doctor says my blood work has improved across the board.
BOXED WARNING — RISK OF THYROID C-CELL TUMORS: Based on animal studies, retatrutide and other GLP-1 receptor agonists may cause thyroid C-cell tumors. Relevance to humans has not been determined. Do not use if you or a family member have a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
Retatrutide is a prescription medication and is not FDA-approved. It is prescribed as a compounded preparation and compounded by a state-licensed 503A pharmacy in the United States pursuant to a valid prescription from a U.S.-licensed physician for an individual patient. Compounded drugs are not reviewed by the FDA for safety, effectiveness, or quality before being dispensed. Retatrutide is not appropriate for everyone — including patients with a personal or family history of medullary thyroid carcinoma, MEN2, severe gastrointestinal disease, or who are pregnant or breastfeeding. Side effects may include nausea, diarrhea, constipation, vomiting, and, less commonly, pancreatitis or gallbladder disease. Individual results vary. Talk to a licensed clinician before starting any prescription therapy. ArgoMD does not bill insurance. © 2026 ArgoMD. Privacy Policy · Terms of Service · Contact Us.
Join thousands of patients who have achieved their weight loss goals with ArgoMD.
e5/month